9592.Se

The company maintains a debt-to-equity ratio of 1.35, indicating a moderate reliance on debt financing relative to equity. Its liquidity position is characterized as medium, with a current ratio of 1.07, suggesting that the company has just enough current assets to cover its current liabilities. Free cash flow stands at 31,346,970, which is a positive sign of operational efficiency and capacity for reinvestment or shareholder returns.

Profitability metrics show a return on equity of 5.74% and a return on assets of 1.63%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These figures suggest that the company is not generating strong returns relative to its equity or asset base.

The company's revenue is not segmented by product or geographic region in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the lack of segmentation data may indicate a relatively undiversified business model or limited disclosure.

The company's growth trajectory is not explicitly outlined in the available data, but the current financial snapshot does not indicate significant revenue growth or contraction. The operating cash flow of 24,991,460 and free cash flow of 31,346,970 suggest a stable cash-generating business.

Risk factors include a medium liquidity risk and a low dilution risk. The company has a negative net cash position after subtracting total debt, which could pose challenges in maintaining liquidity under stress scenarios. No dilution risk is flagged, and no adjustments have been applied to the valuation metrics.

Recent events or filings are not detailed in the available data, so no specific recent developments can be cited.